MX2019015348A - Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1). - Google Patents
Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1).Info
- Publication number
- MX2019015348A MX2019015348A MX2019015348A MX2019015348A MX2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A MX 2019015348 A MX2019015348 A MX 2019015348A
- Authority
- MX
- Mexico
- Prior art keywords
- ror1
- tyrosine kinase
- receptor
- antibodies against
- orphan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1710835.8A GB201710835D0 (en) | 2017-07-05 | 2017-07-05 | ROR1 Antibodies |
| PCT/GB2018/051914 WO2019008377A1 (en) | 2017-07-05 | 2018-07-05 | ANTIBODY ROR1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019015348A true MX2019015348A (es) | 2020-07-20 |
Family
ID=59592560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015348A MX2019015348A (es) | 2017-07-05 | 2018-07-05 | Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1). |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11466083B2 (https=) |
| EP (1) | EP3649152B1 (https=) |
| JP (1) | JP7242573B2 (https=) |
| CN (1) | CN110891973B (https=) |
| AU (1) | AU2018297630B2 (https=) |
| CA (1) | CA3068196A1 (https=) |
| DK (1) | DK3649152T3 (https=) |
| ES (1) | ES3048696T3 (https=) |
| GB (1) | GB201710835D0 (https=) |
| MX (1) | MX2019015348A (https=) |
| WO (1) | WO2019008377A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
| US20230416942A1 (en) * | 2020-08-21 | 2023-12-28 | Yale University | Nanobody Compositions and Methods of Use of the Same |
| KR20230053602A (ko) * | 2020-08-24 | 2023-04-21 | 에피맙 바이오테라퓨틱스 (에이치케이) 리미티드 | 항-ror1 항체 및 관련된 이중특이적 결합 단백질 |
| TWI818308B (zh) * | 2020-09-03 | 2023-10-11 | 大陸商和鉑醫藥（上海）有限責任公司 | 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用 |
| CA3199586A1 (en) * | 2020-11-23 | 2022-05-27 | Samantha J. Busfield | Antigen-binding molecules and uses thereof |
| WO2022182562A1 (en) * | 2021-02-23 | 2022-09-01 | BioLegend, Inc. | ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| US20240309116A1 (en) * | 2021-07-23 | 2024-09-19 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against ror1 and uses thereof |
| CN113956359B (zh) * | 2021-10-29 | 2022-09-16 | 叶鑫淼 | 一种抗体及其在抗肿瘤中的应用 |
| CN118302448A (zh) * | 2021-12-28 | 2024-07-05 | 江苏恒瑞医药股份有限公司 | 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途 |
| WO2024012434A1 (en) * | 2022-07-11 | 2024-01-18 | Hansoh Bio Llc | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| CN115724973B (zh) * | 2022-09-26 | 2023-07-11 | 普健生物（武汉）科技有限公司 | 抗人ror1高亲和力兔单克隆抗体及其应用 |
| CN118440200B (zh) * | 2023-04-21 | 2025-05-16 | 星奕昂(上海)生物科技有限公司 | 靶向ror1的抗体及其应用 |
| CN121666398A (zh) * | 2023-08-31 | 2026-03-13 | 正大天晴药业集团股份有限公司 | 靶向受体酪氨酸激酶样孤儿受体1的抗体及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004030811D1 (de) | 2003-10-16 | 2011-02-10 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
| WO2007146957A2 (en) | 2006-06-13 | 2007-12-21 | Irm Llc | Ror1 as a therapeutic target for lung cancer |
| WO2010124188A1 (en) * | 2009-04-23 | 2010-10-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| US20120282177A1 (en) * | 2009-11-02 | 2012-11-08 | Christian Rohlff | ROR1 as Therapeutic and Diagnostic Target |
| EP2513146B1 (en) | 2009-12-18 | 2017-05-03 | Kancera AB | Antibodies against ror1 capable of inducing cell death of cll |
| EP3828205A1 (en) | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| US9758586B2 (en) | 2010-12-01 | 2017-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ROR1 antibodies |
| GB201020995D0 (en) | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| DK3252076T3 (da) | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| KR102048855B1 (ko) * | 2014-07-29 | 2019-11-26 | 셀렉티스 | 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체 |
| JP2017522893A (ja) | 2014-07-31 | 2017-08-17 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｒｏｒ１特異的多重鎖キメラ抗原受容体 |
| RU2753512C2 (ru) | 2014-09-08 | 2021-08-17 | Нэшнл Кэнсер Сентер | Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования |
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| EP3204416A1 (en) | 2014-10-09 | 2017-08-16 | EngMab AG | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| JP6865688B2 (ja) | 2015-01-16 | 2021-04-28 | ジュノー セラピューティクス インコーポレイテッド | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| EP3253754B1 (en) | 2015-02-02 | 2021-03-31 | Kancera AB | 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity |
| EP3842072A1 (en) * | 2015-05-18 | 2021-06-30 | Eureka Therapeutics, Inc. | Anti-ror1 antibodies |
| CN108137669B (zh) | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | 抗ror1嵌合抗原受体 |
| EA201891066A1 (ru) | 2015-10-30 | 2018-10-31 | ЭнБиИ-ТЕРАПЬЮТИКС АГ | Антитела к ror1 |
| SG11201806120WA (en) | 2016-01-20 | 2018-08-30 | Scripps Research Inst | Ror1 antibody compositions and related methods |
| KR20180100238A (ko) | 2016-01-22 | 2018-09-07 | 얀센 바이오테크 인코포레이티드 | 항-ror1 항체, ror1 × cd3 이중특이성 항체, 및 이를 사용하는 방법 |
| TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ｒｏｒ１－結合分子及其使用方法 |
| WO2017156479A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| CN109563092B (zh) | 2016-07-11 | 2021-09-14 | 坎塞拉有限公司 | 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物 |
| WO2018119314A1 (en) | 2016-12-22 | 2018-06-28 | Ardeagen Corporation | Anti-ror1 antibody and conjugates thereof |
| MX2019013998A (es) | 2017-05-23 | 2020-07-29 | Dragonfly Therapeutics Inc | Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2). |
| MX2019015057A (es) | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| WO2019005636A2 (en) | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE |
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| WO2019016381A1 (en) | 2017-07-20 | 2019-01-24 | Nbe-Therapeutics Ag | MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES |
| EP3665193A1 (en) | 2017-08-07 | 2020-06-17 | NBE Therapeutics AG | Anthracycline-based antibody drug conjugates having high in vivo tolerability |
| AU2018360031B2 (en) | 2017-11-03 | 2025-08-21 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-ROR1 immunotherapy |
| GB201721802D0 (en) | 2017-12-22 | 2018-02-07 | Almac Discovery Ltd | Ror1-specific antigen binding molecules |
| WO2019225777A1 (ko) | 2018-05-23 | 2019-11-28 | 에이비엘바이오 주식회사 | 항-ror1 항체 및 그 용도 |
-
2017
- 2017-07-05 GB GBGB1710835.8A patent/GB201710835D0/en not_active Ceased
-
2018
- 2018-07-05 CA CA3068196A patent/CA3068196A1/en active Pending
- 2018-07-05 JP JP2019572456A patent/JP7242573B2/ja active Active
- 2018-07-05 EP EP18742575.6A patent/EP3649152B1/en active Active
- 2018-07-05 CN CN201880045361.4A patent/CN110891973B/zh active Active
- 2018-07-05 ES ES18742575T patent/ES3048696T3/es active Active
- 2018-07-05 DK DK18742575.6T patent/DK3649152T3/da active
- 2018-07-05 MX MX2019015348A patent/MX2019015348A/es unknown
- 2018-07-05 US US16/628,512 patent/US11466083B2/en active Active
- 2018-07-05 AU AU2018297630A patent/AU2018297630B2/en active Active
- 2018-07-05 WO PCT/GB2018/051914 patent/WO2019008377A1/en not_active Ceased
-
2022
- 2022-07-21 US US17/869,872 patent/US20230220073A1/en not_active Abandoned
-
2024
- 2024-08-26 US US18/815,603 patent/US20250066472A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230220073A1 (en) | 2023-07-13 |
| EP3649152B1 (en) | 2025-10-08 |
| AU2018297630B2 (en) | 2025-03-06 |
| WO2019008377A1 (en) | 2019-01-10 |
| CN110891973A (zh) | 2020-03-17 |
| CN110891973B (zh) | 2023-06-27 |
| JP7242573B2 (ja) | 2023-03-20 |
| ES3048696T3 (en) | 2025-12-11 |
| DK3649152T3 (da) | 2025-11-10 |
| AU2018297630A1 (en) | 2020-01-16 |
| US11466083B2 (en) | 2022-10-11 |
| CA3068196A1 (en) | 2019-01-10 |
| JP2020530272A (ja) | 2020-10-22 |
| GB201710835D0 (en) | 2017-08-16 |
| US20250066472A1 (en) | 2025-02-27 |
| US20200354448A1 (en) | 2020-11-12 |
| EP3649152A1 (en) | 2020-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015348A (es) | Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1). | |
| CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| JOP20200312A1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
| EA202091540A1 (ru) | Антитела к lilrb2 | |
| CY1122804T1 (el) | Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα) | |
| SA518400222B1 (ar) | أجسام مضادة لـ وتركيبات tim-3 | |
| EA202090204A1 (ru) | Анти-cd137 антитела | |
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| WO2017031458A3 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| MX2019015349A (es) | Anticuerpos biespecificos para receptor 1 huerfano tipo receptor de tirosina cinasa (ror1) y grupo de diferenciacion 3 (cd3). | |
| NZ739750A (en) | Anti-tigit antibodies and methods of use | |
| MX2019015352A (es) | Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1). | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| TN2017000010A1 (en) | Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use. | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| IL257274B (en) | Compositions and methods for treating cancers associated with etbr activation | |
| EA201792300A1 (ru) | Комбинации иммуноконъюгата к cd37 и антитела к cd20 | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| NZ763061A (en) | Anti-ox40 antibodies and uses thereof | |
| MX2024003627A (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso. | |
| MA55558A (fr) | Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeurs | |
| EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка |